About IntelGenx Technologies Corp. (CVE:IGX)
IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The companys products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimers disease. It is also developing various products, including INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015, and INT0044/2016 based on three delivery platform technologies, which consist of VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology; and AdVersa, a mucoadhesive tablet technology. The company has co-development and commercialization agreements with RedHill Biopharma Ltd.; Par Pharmaceutical Companies, Inc.; and Endo Ventures Ltd., as well as a licensing, development, and supply agreement with Chemo Group. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Saint-Laurent, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Frequently Asked Questions for IntelGenx Technologies Corp. (CVE:IGX)
What is IntelGenx Technologies Corp.'s stock symbol?
IntelGenx Technologies Corp. trades on the Canadian Venture Exchange (CVE) under the ticker symbol "IGX."
When will IntelGenx Technologies Corp. make its next earnings announcement?
Who are some of IntelGenx Technologies Corp.'s key competitors?
Some companies that are related to IntelGenx Technologies Corp. include Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp. (CXR), Soligenix (SNGX), Senesco Technologies (SVON), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), TetraLogic Pharmaceuticals Corporation (TLOG), Cubist Pharmaceuticals (CBST), Idenix Pharmaceuticals (IDIX) and Onyx Pharmaceuticals (ONXX).
How do I buy IntelGenx Technologies Corp. stock?
Shares of IntelGenx Technologies Corp. and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IntelGenx Technologies Corp.'s stock price today?
One share of IntelGenx Technologies Corp. stock can currently be purchased for approximately C$0.90.
How big of a company is IntelGenx Technologies Corp.?
IntelGenx Technologies Corp. has a market capitalization of C$57.25 million.
MarketBeat Community Rating for IntelGenx Technologies Corp. (IGX)MarketBeat's community ratings are surveys of what our community members think about IntelGenx Technologies Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for IntelGenx Technologies Corp. (CVE:IGX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for IntelGenx Technologies Corp. (CVE:IGX)
Analysts' Ratings History for IntelGenx Technologies Corp. (CVE:IGX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for IntelGenx Technologies Corp. (CVE:IGX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for IntelGenx Technologies Corp. (CVE:IGX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for IntelGenx Technologies Corp. (CVE:IGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for IntelGenx Technologies Corp. (CVE IGX)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for IntelGenx Technologies Corp. (CVE IGX)
Financials are not available for this stock.
IntelGenx Technologies Corp. (CVE IGX) Chart for Thursday, November, 23, 2017